GO
Loading...

Pfizer Inc

More

  • Biogen shares up; Alzheimer's drug shows promise Tuesday, 2 Dec 2014 | 9:46 AM ET

    Biogen Idec said its experimental medicine for Alzheimer's disease showed promise, prompting it to move "aggressively" into the most advanced stage of studies.

  • AstraZeneca on failed Pfizer deal  Friday, 28 Nov 2014 | 4:35 AM ET

    The tax inversion announcement seriously reduced the likelihood of the Pfizer AstraZeneca deal going ahead says CNBC's Catherine Boyle.

  • Pascal Soriot, CEO of Astrazeneca, says there will be less need for mergers and acquisitions as the company's internal drug pipeline is strong.

  • I'm a strong believer in Europe: Astrazeneca CEO  Friday, 28 Nov 2014 | 2:45 AM ET

    Discussing a possible British exit from the European Union, Pascal Soriot, CEO of Astrazeneca, says he is a believer in Europe and immigration is key to getting the best talent for his company.

  • Astrazeneca could eye tech firms for M&A: Expert  Friday, 28 Nov 2014 | 2:30 AM ET

    Mike Ward, global director of content at SCRIP Intelligence, says pharmaceutical companies could look towards the technology sector for interesting mergers, acquisitions or partnerships.

  • Pfizer deal would have failed: Astrazeneca CEO  Friday, 28 Nov 2014 | 1:05 AM ET

    Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.

  • Pfizer deal would probably have failed: AZ CEO Friday, 28 Nov 2014 | 1:01 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.

  • Early Movers: DE, HPQ, HTZ, V, AMZN, TWTR & more Wednesday, 26 Nov 2014 | 8:05 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Pfizer to join forces with AstraZeneca?  Wednesday, 26 Nov 2014 | 4:35 AM ET

    American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".

  • Back for more: Will Pfizer top its AstraZeneca bid? Wednesday, 26 Nov 2014 | 3:34 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer’s $110 billion bid for AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?

  • Pfizer to renew pursuit of AstraZeneca?  Wednesday, 26 Nov 2014 | 1:20 AM ET

    Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?

  • Cramer Remix: Warning about Friday's rally Friday, 21 Nov 2014 | 6:48 PM ET
    Jim Cramer on Mad Money.

    Before you get too excited about Friday's move, "Mad Money" host Jim Cramer puts it in context.

  • FDA approves Purdue's painkiller that can reduce abuse Thursday, 20 Nov 2014 | 1:46 PM ET

    Nov 20- The U.S. Food and Drug Administration has approved a long-acting narcotic painkiller with abuse-resistant properties made by Purdue Pharma L.P., the agency said on Thursday. The FDA approved the once-daily drug, Hysingla ER, with the expectation that it will reduce, though not necessarily prevent, abuse through snorting or injecting.

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. AstraZeneca, which saw off a $118 billion approach from Pfizer in May, is his...

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. AstraZeneca is his biggest holding.

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.

  • *Investor day comes 8 days before Pfizer can resume pursuit. LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. It reiterated it was on course to return to growth and that annual sales would rise by three quarters...

  • AstraZeneca trumpets progress in cancer, other drugs Tuesday, 18 Nov 2014 | 2:20 AM ET

    LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. AstraZeneca executives will present further details at a six-hour investor meeting later on Tuesday. The event comes just eight days before British takeover...

  • Stocks little moved; S&P 500 at record-high close Monday, 17 Nov 2014 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks fell Monday after data had Japan unexpectedly falling into a recession.

  • CHICAGO, Nov 17- After years of uncertainty, a nearly decade-long study showed that Merck& Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. Christopher Cannon, lead investigator of the 18,144- patient Improve-It study presented at the American Heart Association...